Core Insights - Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has recently reached a three-year high, driven by investor interest following a dip to $13 earlier in the week, with the stock closing up 14.03% at $18.61 [1][2] Financial Performance - In the third quarter, Adaptive Biotechnologies reported a net income of $9.5 million, a significant turnaround from a net loss of $32.07 million in the same period last year [3] - Revenues for the company increased by 102% year-on-year, reaching $93.97 million, up from $46.4 million, which included $33.7 million from Immune Medicine due to the full amortization of payments under the terminated Genentech Agreement [4] Future Outlook - The company anticipates its pharmaceutical services will generate $20 million in revenues and expects EMR integrated testing volumes to exceed 50% by year-end [2] - Adaptive Biotechnologies is scheduled to participate in the Piper Sandler Healthcare Conference on December 3, indicating ongoing engagement with investors and stakeholders [3]